The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

The worldwide intravenous iron medication market sales is expected to increase from USD 2.6 billion in 2021 to USD 6.3 ...

The drug, called Enhertu, can give patients with a specific type of incurable breast cancer an extra six months to live on ...

The biotech industry offers a compelling investment opportunity due to its potential for disruptive innovations and high ...

The Business Research Company's Contrast Media Global Market Report 2024 – Market Size, Trends, And Forecast 2024-2033 ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

Mauro Vitali, head of Oncology Business Division of Daiichi Sankyo Italia Photos: Courtesy of Daiichi Sankyo. As one of the ...

The T. Rowe Price Japan Fund (Trades, Portfolio), known for its strategic investments in a diverse array of Japanese ...

The long-term risk of distant recurrence for women with early breast cancer has declined significantly, a decades-long ...